Treace Medical Concepts (TMCI) Financials

$1.88 +0.05 (+2.73%)

Closing price 05/5/2026 04:00 PM Eastern

Extended Trading

$1.88 0.00 (0.00%)

As of 05/5/2026 07:21 PM Eastern

Annual Income Statements for Treace Medical Concepts

This table shows Treace Medical Concepts' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-43	-49	-56
Consolidated Net Income / (Loss)	-43	-50	-56
Net Income / (Loss) Continuing Operations	-43	-50	-56
Total Pre-Tax Income	-43	-50	-56
Total Operating Income	-35	-51	-56
Total Gross Profit	116	152	168
Total Revenue	142	187	209
Operating Revenue	142	187	209
Total Cost of Revenue	26	35	41
Operating Cost of Revenue	26	35	41
Total Operating Expenses	151	203	224
Selling, General & Admin Expense	33	47	56
Marketing Expense	105	141	148
Research & Development Expense	14	15	21
Other Operating Expenses / (Income)	-	-0.34	-0.32
Total Other Income / (Expense), net	-7.97	1.90	-0.50
Interest Expense	8.88	5.17	5.26
Interest & Investment Income	1.31	6.73	4.88
Other Income / (Expense), net	-0.40	-	-0.12
Basic Earnings per Share	($0.77)	($0.81)	($0.90)
Weighted Average Basic Shares Outstanding	55.28M	60.85M	62.11M
Diluted Earnings per Share	($0.77)	($0.81)	($0.90)
Weighted Average Diluted Shares Outstanding	55.28M	60.85M	62.11M
Weighted Average Basic & Diluted Shares Outstanding	61.16M	61.76M	62.62M

This table shows Treace Medical Concepts' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-12	-8.11	-13	-12	-17	-5.97	-19	-21	-15	-0.50
Consolidated Net Income / (Loss)	-12	-4.41	-13	-12	-18	-6.28	-19	-21	-15	-0.50
Net Income / (Loss) Continuing Operations	-12	-8.13	-13	-12	-18	-6.51	-19	-21	-15	-1.01
Total Pre-Tax Income	-12	-8.13	-13	-12	-18	-6.51	-19	-21	-15	-1.01
Total Operating Income	-11	-3.50	-14	-13	-18	-6.78	-19	-21	-15	-0.20
Total Gross Profit	27	41	34	34	33	51	41	36	36	55
Total Revenue	33	50	42	42	41	62	51	44	45	69
Operating Revenue	33	50	42	42	41	62	51	44	45	69
Total Cost of Revenue	6.09	9.02	8.04	7.68	8.00	11	10	8.78	8.95	13
Operating Cost of Revenue	6.09	9.02	8.04	7.68	8.00	11	10	8.78	8.95	13
Total Operating Expenses	38	44	48	47	51	57	60	57	51	56
Selling, General & Admin Expense	8.92	10	11	10	13	13	14	14	14	14
Marketing Expense	26	30	34	34	34	40	40	38	33	37
Research & Development Expense	3.80	3.75	3.41	3.53	4.35	4.15	5.26	5.16	4.96	5.21
Other Operating Expenses / (Income)	0.05	-	-	-0.10	-0.02	-	-0.07	-0.11	-0.02	-0.12
Total Other Income / (Expense), net	-0.82	-4.58	0.32	0.78	0.30	0.50	0.42	0.15	-0.26	-0.81
Interest Expense	1.19	10	1.29	1.28	1.30	1.30	1.32	1.31	1.31	1.31
Interest & Investment Income	0.42	0.75	1.48	1.97	1.57	1.71	1.54	1.38	1.07	0.90
Other Income / (Expense), net	-	-	0.13	-	-	-	0.20	0.08	-0.01	-0.39
Basic Earnings per Share	($0.22)	($0.08)	($0.23)	($0.20)	($0.28)	($0.10)	($0.30)	($0.34)	($0.25)	($0.01)
Weighted Average Basic Shares Outstanding	55.43M	55.28M	58.72M	61.38M	61.56M	60.85M	61.79M	62.08M	62.23M	62.11M
Diluted Earnings per Share	($0.22)	($0.08)	($0.23)	($0.20)	($0.28)	($0.10)	($0.30)	($0.34)	($0.25)	($0.01)
Weighted Average Diluted Shares Outstanding	55.43M	55.28M	58.72M	61.38M	61.56M	60.85M	61.79M	62.08M	62.23M	62.11M
Weighted Average Basic & Diluted Shares Outstanding	55.50M	61.16M	61.33M	61.54M	61.68M	61.76M	62.01M	62.19M	62.30M	62.62M

This table details how cash moves in and out of Treace Medical Concepts' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-86	-6.49	-1.63
Net Cash From Operating Activities	-31	-35	-37
Net Cash From Continuing Operating Activities	-31	-35	-37
Net Income / (Loss) Continuing Operations	-43	-50	-56
Consolidated Net Income / (Loss)	-43	-50	-56
Depreciation Expense	2.13	5.35	8.42
Amortization Expense	0.12	-1.11	-0.85
Non-Cash Adjustments To Reconcile Net Income	16	20	34
Changes in Operating Assets and Liabilities, net	-5.81	-9.74	-23
Net Cash From Investing Activities	-77	-81	35
Net Cash From Continuing Investing Activities	-77	-81	35
Purchase of Property, Plant & Equipment	-15	-11	-12
Acquisitions	0.00	-20	0.00
Purchase of Investments	-63	-170	-72
Sale and/or Maturity of Investments	1.73	120	119
Net Cash From Financing Activities	21	109	0.16
Net Cash From Continuing Financing Activities	21	109	0.16
Repayment of Debt	-0.99	0.00	0.00
Issuance of Debt	50	0.00	0.00
Issuance of Common Equity	0.00	108	0.00
Other Financing Activities, net	-28	1.86	0.16
Cash Interest Paid	4.40	5.17	4.96

This table details how cash moves in and out of Treace Medical Concepts' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-4.29	-69	10	-18	-4.76	5.70	-3.65	8.85	-6.07	-0.76
Net Cash From Operating Activities	-7.48	-5.36	-17	-8.34	-9.51	0.53	-7.22	-14	-12	-4.21
Net Cash From Continuing Operating Activities	1.51	-5.65	-17	-8.47	-9.51	0.53	-7.22	-14	-12	-4.21
Net Income / (Loss) Continuing Operations	-12	-4.41	-13	-12	-18	-6.28	-19	-21	-15	-0.50
Consolidated Net Income / (Loss)	-12	-4.41	-13	-12	-18	-6.28	-19	-21	-15	-0.50
Depreciation Expense	0.46	0.92	0.92	1.10	1.56	1.77	1.91	2.12	2.16	2.24
Amortization Expense	0.07	-0.05	-0.22	-0.29	-0.29	-0.30	-0.26	-0.28	-0.16	-0.15
Non-Cash Adjustments To Reconcile Net Income	12	3.98	4.04	4.66	4.88	6.86	8.25	8.16	8.81	8.75
Changes in Operating Assets and Liabilities, net	1.00	-6.09	-8.41	-1.67	1.85	-1.52	1.56	-2.69	-7.29	-15
Net Cash From Investing Activities	-5.86	-64	-80	-10	4.60	5.01	3.76	22	5.76	3.42
Net Cash From Continuing Investing Activities	-5.86	-64	-80	-10	4.60	5.01	3.76	22	5.76	3.42
Purchase of Property, Plant & Equipment	-5.86	-2.33	-1.48	-4.23	-3.50	-2.25	-3.93	-1.73	-2.86	-3.07
Purchase of Investments	-	-63	-100	-21	-19	-30	-29	-	-24	-19
Sale and/or Maturity of Investments	-	1.73	21	35	27	37	36	24	33	25
Net Cash From Financing Activities	0.35	0.30	108	1.18	0.16	0.17	-0.19	0.31	0.01	0.03
Net Cash From Continuing Financing Activities	0.35	0.30	108	1.18	0.16	0.17	-0.19	0.31	0.01	0.03
Other Financing Activities, net	0.35	-34	0.35	1.18	0.16	0.17	-0.19	0.31	0.01	0.03
Cash Interest Paid	1.19	1.31	1.29	1.28	1.30	1.30	1.32	1.17	1.24	1.22

This table presents Treace Medical Concepts' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	159	252	217
Total Current Assets	133	198	161
Cash & Equivalents	19	13	11
Short-Term Investments	62	110	64
Accounts Receivable	29	38	41
Inventories, net	19	29	39
Prepaid Expenses	3.62	7.85	5.67
Plant, Property, & Equipment, net	15	22	26
Total Noncurrent Assets	10	31	30
Goodwill	0.00	13	13
Intangible Assets	0.00	9.03	8.08
Other Noncurrent Operating Assets	10	9.41	8.85
Total Liabilities & Shareholders' Equity	159	252	217
Total Liabilities	98	114	104
Total Current Liabilities	30	45	35
Accounts Payable	8.67	12	11
Accrued Expenses	14	21	17
Current Employee Benefit Liabilities	7.67	7.55	6.58
Other Current Liabilities	0.34	4.43	0.51
Total Noncurrent Liabilities	68	69	69
Long-Term Debt	53	53	53
Other Noncurrent Operating Liabilities	16	16	16
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	61	138	113
Total Preferred & Common Equity	61	138	113
Preferred Stock	0.00	0.00	0.00
Total Common Equity	61	138	113
Common Stock	145	272	303
Retained Earnings	-85	-134	-190
Treasury Stock	0.00	-0.01	-0.28
Accumulated Other Comprehensive Income / (Loss)	-0.03	0.16	0.10

This table presents Treace Medical Concepts' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	156	249	250	240	243	226	213
Total Current Assets	128	223	198	187	187	172	158
Cash & Equivalents	89	30	12	7.28	9.33	18	12
Short-Term Investments	-	141	127	115	101	77	71
Accounts Receivable	19	25	27	25	30	26	24
Inventories, net	17	23	26	29	36	41	44
Prepaid Expenses	4.01	4.59	5.28	11	11	9.67	7.02
Plant, Property, & Equipment, net	14	16	19	22	25	24	25
Total Noncurrent Assets	14	10	32	32	31	30	30
Goodwill	-	-	13	13	13	13	13
Intangible Assets	-	-	9.50	9.26	8.79	8.55	8.31
Other Noncurrent Operating Assets	14	10	9.80	9.61	9.21	8.92	9.03
Total Liabilities & Shareholders' Equity	156	249	250	240	243	226	213
Total Liabilities	94	92	100	103	116	114	108
Total Current Liabilities	23	23	30	33	47	44	38
Accounts Payable	7.88	5.08	8.15	8.68	21	18	19
Accrued Expenses	9.32	14	13	14	21	20	13
Current Employee Benefit Liabilities	5.05	3.30	5.37	5.07	4.20	6.19	5.60
Other Current Liabilities	0.33	-	3.78	5.19	1.02	0.52	0.57
Total Noncurrent Liabilities	72	68	70	69	69	69	70
Long-Term Debt	53	53	53	53	53	53	53
Other Noncurrent Operating Liabilities	19	15	17	16	16	16	17
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	62	158	150	138	126	112	105
Total Preferred & Common Equity	62	158	150	138	126	112	105
Preferred Stock	0.00	-	-	0.00	0.00	0.00	0.00
Total Common Equity	62	158	150	138	126	112	105
Common Stock	143	256	261	266	279	287	294
Retained Earnings	-80	-98	-110	-128	-153	-174	-189
Treasury Stock	-	-	-	-	-0.25	-0.25	-0.25
Accumulated Other Comprehensive Income / (Loss)	-	-0.06	-0.22	-0.15	0.07	-0.03	0.19

This table displays calculated financial ratios and metrics derived from Treace Medical Concepts' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	50.22%	31.92%	11.89%
EBITDA Growth	-110.85%	-43.00%	-2.23%
EBIT Growth	-113.49%	-45.91%	-8.52%
NOPAT Growth	-111.05%	-47.60%	-8.28%
Net Income Growth	-108.33%	-15.68%	-12.55%
EPS Growth	-79.07%	-5.19%	-11.11%
Operating Cash Flow Growth	-78.26%	-12.81%	-7.50%
Free Cash Flow Firm Growth	-174.53%	-80.42%	13.94%
Invested Capital Growth	92.64%	111.79%	33.61%
Revenue Q/Q Growth	13.01%	7.12%	3.20%
EBITDA Q/Q Growth	6.37%	-6.03%	12.79%
EBIT Q/Q Growth	4.59%	-6.82%	10.37%
NOPAT Q/Q Growth	5.68%	-6.82%	10.56%
Net Income Q/Q Growth	4.90%	-3.92%	9.39%
EPS Q/Q Growth	7.23%	-2.53%	9.09%
Operating Cash Flow Q/Q Growth	-5.53%	14.56%	-14.61%
Free Cash Flow Firm Q/Q Growth	-13.91%	5.63%	-22.79%
Invested Capital Q/Q Growth	21.67%	-1.29%	20.15%
Profitability Metrics	-	-	-
Gross Margin	82.00%	81.20%	80.37%
EBITDA Margin	-23.26%	-25.22%	-23.04%
Operating Margin	-24.57%	-27.48%	-26.60%
EBIT Margin	-24.85%	-27.48%	-26.66%
Profit (Net Income) Margin	-30.19%	-26.47%	-26.63%
Tax Burden Percent	100.00%	99.31%	99.21%
Interest Burden Percent	121.47%	96.97%	100.68%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-100.39%	-72.19%	-49.26%
ROIC Less NNEP Spread (ROIC-NNEP)	-65.30%	-44.79%	-13.04%
Return on Net Nonoperating Assets (RNNOA)	44.64%	22.28%	4.81%
Return on Equity (ROE)	-55.75%	-49.91%	-44.45%
Cash Return on Invested Capital (CROIC)	-163.70%	-143.90%	-78.04%
Operating Return on Assets (OROA)	-23.51%	-25.03%	-23.80%
Return on Assets (ROA)	-28.56%	-24.10%	-23.77%
Return on Common Equity (ROCE)	-55.73%	-49.91%	-44.45%
Return on Equity Simple (ROE_SIMPLE)	-70.73%	-35.91%	-49.38%
Net Operating Profit after Tax (NOPAT)	-24	-36	-39
NOPAT Margin	-17.20%	-19.24%	-18.62%
Net Nonoperating Expense Percent (NNEP)	-35.09%	-27.40%	-36.22%
Return On Investment Capital (ROIC_SIMPLE)	-21.54%	-18.85%	-23.45%
Cost of Revenue to Revenue	18.00%	18.80%	19.63%
SG&A Expenses to Revenue	23.27%	25.13%	26.61%
R&D to Revenue	9.58%	8.25%	9.83%
Operating Expenses to Revenue	106.57%	108.50%	106.82%
Earnings before Interest and Taxes (EBIT)	-35	-51	-56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-33	-47	-48
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	21.08	5.70	4.11
Price to Tangible Book Value (P/TBV)	21.08	6.77	5.04
Price to Revenue (P/Rev)	9.00	4.20	2.21
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	39.00	10.57	4.87
Enterprise Value to Revenue (EV/Rev)	8.79	3.83	2.11
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.87	0.38	0.47
Long-Term Debt to Equity	0.87	0.38	0.47
Financial Leverage	-0.68	-0.50	-0.37
Leverage Ratio	1.95	2.07	1.87
Compound Leverage Factor	2.37	2.01	1.88
Debt to Total Capital	46.55%	27.76%	32.07%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	46.55%	27.76%	32.07%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	53.45%	72.24%	67.93%
Debt to EBITDA	-1.60	-1.12	-1.11
Net Debt to EBITDA	0.87	1.49	0.46
Long-Term Debt to EBITDA	-1.60	-1.12	-1.11
Debt to NOPAT	-2.16	-1.47	-1.37
Net Debt to NOPAT	1.17	1.95	0.57
Long-Term Debt to NOPAT	-2.16	-1.47	-1.37
Altman Z-Score	7.97	4.19	2.26
Noncontrolling Interest Sharing Ratio	0.03%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	4.41	4.40	4.62
Quick Ratio	3.65	3.58	3.34
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-40	-72	-62
Operating Cash Flow to CapEx	-206.55%	-301.75%	-320.60%
Free Cash Flow to Firm to Interest Expense	-4.48	-13.89	-11.75
Operating Cash Flow to Interest Expense	-3.45	-6.69	-7.07
Operating Cash Flow Less CapEx to Interest Expense	-5.12	-8.91	-9.28
Efficiency Ratios	-	-	-
Asset Turnover	0.95	0.91	0.89
Accounts Receivable Turnover	5.94	5.56	5.31
Inventory Turnover	1.71	1.45	1.20
Fixed Asset Turnover	15.60	9.94	8.68
Accounts Payable Turnover	4.01	3.43	3.68
Days Sales Outstanding (DSO)	61.46	65.60	68.75
Days Inventory Outstanding (DIO)	213.66	251.98	304.22
Days Payable Outstanding (DPO)	90.95	106.36	99.29
Cash Conversion Cycle (CCC)	184.16	211.22	273.68
Capital & Investment Metrics	-	-	-
Invested Capital	32	68	91
Invested Capital Turnover	5.84	3.75	2.65
Increase / (Decrease) in Invested Capital	15	36	23
Enterprise Value (EV)	1,247	716	441
Market Capitalization	1,276	786	463
Book Value per Share	$1.09	$2.24	$1.81
Tangible Book Value per Share	$1.09	$1.88	$1.48
Total Capital	113	191	166
Total Debt	53	53	53
Total Long-Term Debt	53	53	53
Net Debt	-29	-70	-22
Capital Expenditures (CapEx)	15	11	12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	22	30	51
Debt-free Net Working Capital (DFNWC)	103	153	126
Net Working Capital (NWC)	103	153	126
Net Nonoperating Expense (NNE)	18	14	17
Net Nonoperating Obligations (NNO)	-29	-70	-22
Total Depreciation and Amortization (D&A)	2.25	4.24	7.57
Debt-free, Cash-free Net Working Capital to Revenue	15.44%	16.10%	24.26%
Debt-free Net Working Capital to Revenue	72.73%	81.94%	60.41%
Net Working Capital to Revenue	72.73%	81.94%	60.41%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.77)	($0.81)	($0.90)
Adjusted Weighted Average Basic Shares Outstanding	55.28M	60.85M	62.11M
Adjusted Diluted Earnings per Share	($0.77)	($0.81)	($0.90)
Adjusted Weighted Average Diluted Shares Outstanding	55.28M	60.85M	62.11M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	61.16M	61.76M	62.62M
Normalized Net Operating Profit after Tax (NOPAT)	-24	-36	-39
Normalized NOPAT Margin	-17.20%	-19.24%	-18.62%
Pre Tax Income Margin	-30.19%	-26.65%	-26.84%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-3.97	-9.95	-10.62
NOPAT to Interest Expense	-2.75	-6.97	-7.42
EBIT Less CapEx to Interest Expense	-5.64	-12.17	-12.82
NOPAT Less CapEx to Interest Expense	-4.42	-9.18	-9.62
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Treace Medical Concepts' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	52.90%	48.84%	45.26%	40.00%	23.30%	25.00%	21.12%	5.96%	10.62%	10.44%
EBITDA Growth	-106.37%	50.15%	-67.77%	26.92%	-53.43%	-101.98%	-32.24%	-58.88%	20.56%	128.04%
EBIT Growth	-107.29%	37.52%	-68.58%	24.27%	-57.43%	-93.94%	-37.53%	-63.20%	15.01%	91.23%
NOPAT Growth	-107.29%	37.52%	-70.16%	-9.38%	-57.43%	-93.94%	-37.69%	-63.82%	15.06%	96.99%
Net Income Growth	-89.05%	33.34%	-48.89%	28.80%	-44.41%	-42.36%	-38.81%	-72.81%	12.33%	92.02%
EPS Growth	-83.33%	42.86%	-43.75%	35.48%	-27.27%	-25.00%	-30.43%	-70.00%	10.71%	90.00%
Operating Cash Flow Growth	19.23%	-42.80%	-138.35%	21.11%	-27.13%	109.93%	58.16%	-66.73%	-24.48%	-890.79%
Free Cash Flow Firm Growth	19.37%	-160.35%	-195.06%	-168.44%	-222.83%	-127.18%	-28.30%	56.01%	68.44%	43.43%
Invested Capital Growth	52.54%	92.64%	129.91%	178.52%	161.04%	111.79%	70.27%	10.91%	9.77%	33.61%
Revenue Q/Q Growth	10.30%	50.56%	-15.22%	-0.57%	-2.85%	52.64%	-17.85%	-13.02%	1.42%	52.39%
EBITDA Q/Q Growth	35.65%	75.61%	-392.09%	5.39%	-35.09%	67.89%	-222.19%	-13.67%	32.45%	111.34%
EBIT Q/Q Growth	34.33%	69.10%	-290.28%	4.37%	-36.52%	61.94%	-176.76%	-13.48%	28.91%	96.07%
NOPAT Q/Q Growth	5.15%	69.10%	-293.94%	5.26%	-36.52%	61.94%	-179.68%	-12.73%	29.22%	98.65%
Net Income Q/Q Growth	29.60%	63.64%	-204.94%	8.79%	-42.78%	64.15%	-197.34%	-13.55%	27.57%	96.74%
EPS Q/Q Growth	29.03%	63.64%	-187.50%	13.04%	-40.00%	64.29%	-200.00%	-13.33%	26.47%	96.00%
Operating Cash Flow Q/Q Growth	29.18%	28.40%	-222.12%	51.71%	-14.13%	105.59%	-1,457.33%	-92.45%	14.79%	64.47%
Free Cash Flow Firm Q/Q Growth	8.36%	-5.02%	-83.37%	-52.11%	-10.21%	26.10%	-3.56%	47.84%	20.93%	-32.46%
Invested Capital Q/Q Growth	15.61%	21.67%	27.54%	55.25%	8.36%	-1.29%	2.54%	1.13%	7.24%	20.15%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	81.58%	81.87%	80.95%	81.71%	80.38%	81.56%	80.19%	80.25%	80.14%	80.74%
EBITDA Margin	-32.63%	-5.29%	-30.68%	-29.20%	-40.60%	-8.54%	-33.50%	-43.78%	-29.16%	2.17%
Operating Margin	-34.24%	-7.03%	-32.65%	-31.11%	-43.72%	-10.90%	-37.11%	-48.10%	-33.57%	-0.30%
EBIT Margin	-34.24%	-7.03%	-32.35%	-31.11%	-43.72%	-10.90%	-36.73%	-47.92%	-33.59%	-0.87%
Profit (Net Income) Margin	-36.71%	-8.87%	-31.89%	-29.25%	-42.99%	-10.10%	-36.54%	-47.70%	-34.07%	-0.73%
Tax Burden Percent	100.37%	54.30%	100.00%	99.23%	99.87%	96.56%	100.67%	99.85%	99.81%	49.60%
Interest Burden Percent	106.80%	232.34%	98.58%	94.74%	98.46%	95.92%	98.84%	99.70%	101.62%	169.75%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-138.22%	-28.71%	-121.01%	-84.49%	-112.63%	-28.63%	-92.37%	-100.07%	-66.22%	-0.55%
ROIC Less NNEP Spread (ROIC-NNEP)	-130.97%	-24.97%	-116.91%	-79.86%	-103.02%	-25.53%	-86.16%	-90.36%	-56.57%	0.22%
Return on Net Nonoperating Assets (RNNOA)	95.24%	17.07%	88.91%	48.85%	54.14%	12.70%	52.71%	44.31%	23.02%	-0.08%
Return on Equity (ROE)	-42.98%	-11.64%	-32.10%	-35.64%	-58.48%	-15.93%	-39.67%	-55.77%	-43.20%	-0.63%
Cash Return on Invested Capital (CROIC)	-160.44%	-163.70%	-175.67%	-162.05%	-160.22%	-143.90%	-123.89%	-78.42%	-69.87%	-78.04%
Operating Return on Assets (OROA)	-29.23%	-6.65%	-25.34%	-25.44%	-38.49%	-9.93%	-29.27%	-39.99%	-30.06%	-0.77%
Return on Assets (ROA)	-31.34%	-8.39%	-24.98%	-23.92%	-37.85%	-9.19%	-29.13%	-39.81%	-30.49%	-0.65%
Return on Common Equity (ROCE)	-42.98%	-11.64%	-32.09%	-35.64%	-58.48%	-15.93%	-39.66%	-55.77%	-43.20%	-0.63%
Return on Equity Simple (ROE_SIMPLE)	-72.38%	0.00%	-29.97%	-28.19%	-34.57%	0.00%	-43.32%	-56.79%	-58.65%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.92	-2.45	-9.64	-9.14	-12	-4.75	-13	-15	-11	-0.14
NOPAT Margin	-23.97%	-4.92%	-22.85%	-21.78%	-30.60%	-7.63%	-25.98%	-33.67%	-23.50%	-0.21%
Net Nonoperating Expense Percent (NNEP)	-7.26%	-3.74%	-4.10%	-4.62%	-9.60%	-3.11%	-6.21%	-9.71%	-9.65%	-0.77%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.16%	-	-	-	-2.49%	-	-	-	-0.09%
Cost of Revenue to Revenue	18.42%	18.13%	19.05%	18.29%	19.62%	18.44%	19.81%	19.75%	19.86%	19.26%
SG&A Expenses to Revenue	26.97%	20.91%	25.75%	23.91%	31.13%	21.62%	28.10%	31.98%	30.00%	19.81%
R&D to Revenue	11.49%	7.53%	8.09%	8.40%	10.67%	6.67%	10.29%	11.60%	11.01%	7.58%
Operating Expenses to Revenue	115.82%	88.90%	113.60%	112.59%	124.04%	92.11%	117.15%	128.09%	113.66%	80.87%
Earnings before Interest and Taxes (EBIT)	-11	-3.50	-14	-13	-18	-6.78	-19	-21	-15	-0.60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	-2.63	-13	-12	-17	-5.31	-17	-19	-13	1.49
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	19.66	21.08	9.78	10.46	5.85	5.70	6.37	3.68	3.44	4.11
Price to Tangible Book Value (P/TBV)	19.66	21.08	9.78	12.29	6.97	6.77	7.68	4.54	4.31	5.04
Price to Revenue (P/Rev)	9.74	9.00	9.94	9.40	4.62	4.20	4.11	2.08	1.78	2.21
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	45.14	39.00	34.87	23.40	10.75	10.57	10.77	5.27	4.40	4.87
Enterprise Value to Revenue (EV/Rev)	9.46	8.79	9.18	8.88	4.22	3.83	3.82	1.87	1.63	2.11
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.85	0.87	0.33	0.35	0.38	0.38	0.42	0.47	0.51	0.47
Long-Term Debt to Equity	0.85	0.87	0.33	0.35	0.38	0.38	0.42	0.47	0.51	0.47
Financial Leverage	-0.73	-0.68	-0.76	-0.61	-0.53	-0.50	-0.61	-0.49	-0.41	-0.37
Leverage Ratio	1.84	1.95	1.62	1.84	1.98	2.07	1.73	1.82	1.87	1.87
Compound Leverage Factor	1.97	4.54	1.60	1.75	1.95	1.99	1.71	1.81	1.90	3.17
Debt to Total Capital	45.84%	46.55%	25.09%	26.06%	27.74%	27.76%	29.58%	32.16%	33.66%	32.07%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	45.84%	46.55%	25.09%	26.06%	27.74%	27.76%	29.58%	32.16%	33.66%	32.07%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	54.16%	53.45%	74.88%	73.94%	72.26%	72.24%	70.42%	67.84%	66.34%	67.93%
Debt to EBITDA	-1.49	-1.60	-1.39	-1.36	-1.19	-1.12	-1.03	-0.91	-0.96	-1.11
Net Debt to EBITDA	1.02	0.87	3.11	2.24	1.56	1.49	1.11	0.71	0.53	0.46
Long-Term Debt to EBITDA	-1.49	-1.60	-1.39	-1.36	-1.19	-1.12	-1.03	-0.91	-0.96	-1.11
Debt to NOPAT	-2.04	-2.16	-1.86	-1.81	-1.57	-1.47	-1.34	-1.17	-1.22	-1.37
Net Debt to NOPAT	1.39	1.17	4.16	2.97	2.05	1.95	1.44	0.92	0.68	0.57
Long-Term Debt to NOPAT	-2.04	-2.16	-1.86	-1.81	-1.57	-1.47	-1.34	-1.17	-1.22	-1.37
Altman Z-Score	8.44	8.62	10.95	10.13	5.23	4.78	4.52	2.34	2.15	3.10
Noncontrolling Interest Sharing Ratio	0.00%	0.03%	0.04%	0.00%	0.00%	0.00%	0.02%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.66	4.41	9.58	6.60	5.64	4.40	3.98	3.86	4.12	4.62
Quick Ratio	4.74	3.65	8.41	5.55	4.44	3.58	2.98	2.71	2.80	3.34
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-17	-18	-33	-50	-55	-41	-42	-22	-17	-23
Operating Cash Flow to CapEx	-127.76%	-229.76%	-1,167.73%	-197.00%	-271.72%	23.67%	-183.88%	-803.76%	-413.62%	-136.86%
Free Cash Flow to Firm to Interest Expense	-14.27	-1.74	-25.44	-38.79	-42.29	-31.06	-31.85	-16.68	-13.18	-17.44
Operating Cash Flow to Interest Expense	-6.29	-0.52	-13.43	-6.50	-7.34	0.41	-5.48	-10.59	-9.02	-3.20
Operating Cash Flow Less CapEx to Interest Expense	-11.21	-0.75	-14.58	-9.80	-10.04	-1.32	-8.46	-11.91	-11.20	-5.54
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.85	0.95	0.78	0.82	0.88	0.91	0.80	0.83	0.90	0.89
Accounts Receivable Turnover	8.27	5.94	7.49	7.64	8.02	5.56	7.07	7.52	8.25	5.31
Inventory Turnover	1.61	1.71	1.69	1.57	1.42	1.45	1.28	1.14	1.08	1.20
Fixed Asset Turnover	15.33	15.60	15.57	11.85	9.79	9.94	9.70	9.09	8.69	8.68
Accounts Payable Turnover	4.24	4.01	6.67	5.48	3.95	3.43	2.84	2.93	2.88	3.68
Days Sales Outstanding (DSO)	44.12	61.46	48.70	47.80	45.49	65.60	51.62	48.53	44.24	68.75
Days Inventory Outstanding (DIO)	226.42	213.66	215.80	232.49	257.06	251.98	285.87	320.44	338.37	304.22
Days Payable Outstanding (DPO)	86.10	90.95	54.70	66.58	92.33	106.36	128.42	124.69	126.81	99.29
Cash Conversion Cycle (CCC)	184.43	184.16	209.81	213.72	210.22	211.22	209.07	244.28	255.80	273.68
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	26	32	41	63	69	68	69	70	75	91
Invested Capital Turnover	5.77	5.84	5.29	3.88	3.68	3.75	3.56	2.97	2.82	2.65
Increase / (Decrease) in Invested Capital	9.06	15	23	41	42	36	29	6.91	6.71	23
Enterprise Value (EV)	1,187	1,247	1,423	1,482	738	716	748	370	331	441
Market Capitalization	1,223	1,276	1,541	1,569	807	786	805	412	361	463
Book Value per Share	$1.12	$1.09	$2.58	$2.45	$2.24	$2.24	$2.05	$1.81	$1.69	$1.81
Tangible Book Value per Share	$1.12	$1.09	$2.58	$2.08	$1.88	$1.88	$1.70	$1.46	$1.35	$1.48
Total Capital	115	113	210	203	191	191	179	165	158	166
Total Debt	53	53	53	53	53	53	53	53	53	53
Total Long-Term Debt	53	53	53	53	53	53	53	53	53	53
Net Debt	-36	-29	-118	-87	-69	-70	-57	-42	-30	-22
Capital Expenditures (CapEx)	5.86	2.33	1.48	4.23	3.50	2.25	3.93	1.73	2.86	3.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)	17	22	29	29	32	30	30	32	37	51
Debt-free Net Working Capital (DFNWC)	105	103	200	168	154	153	140	127	119	126
Net Working Capital (NWC)	105	103	200	168	154	153	140	127	119	126
Net Nonoperating Expense (NNE)	4.21	1.96	3.81	3.13	5.05	1.53	5.40	6.24	4.77	0.36
Net Nonoperating Obligations (NNO)	-36	-29	-117	-87	-69	-70	-57	-42	-30	-22
Total Depreciation and Amortization (D&A)	0.53	0.87	0.70	0.80	1.27	1.47	1.65	1.84	2.00	2.09
Debt-free, Cash-free Net Working Capital to Revenue	13.37%	15.44%	18.82%	17.13%	18.22%	16.10%	15.48%	16.15%	18.01%	24.26%
Debt-free Net Working Capital to Revenue	83.92%	72.73%	128.94%	100.66%	88.16%	81.94%	71.59%	64.02%	58.83%	60.41%
Net Working Capital to Revenue	83.92%	72.73%	128.94%	100.66%	88.16%	81.94%	71.59%	64.02%	58.83%	60.41%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.22)	($0.08)	($0.23)	($0.20)	($0.28)	($0.10)	($0.30)	($0.34)	($0.25)	($0.01)
Adjusted Weighted Average Basic Shares Outstanding	55.43M	55.28M	58.72M	61.38M	61.56M	60.85M	61.79M	62.08M	62.23M	62.11M
Adjusted Diluted Earnings per Share	($0.22)	($0.08)	($0.23)	($0.20)	($0.28)	($0.10)	($0.30)	($0.34)	($0.25)	($0.01)
Adjusted Weighted Average Diluted Shares Outstanding	55.43M	55.28M	58.72M	61.38M	61.56M	60.85M	61.79M	62.08M	62.23M	62.11M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	55.50M	61.16M	61.33M	61.54M	61.68M	61.76M	62.01M	62.19M	62.30M	62.62M
Normalized Net Operating Profit after Tax (NOPAT)	-7.92	-2.45	-9.64	-9.14	-12	-4.75	-13	-15	-11	-0.14
Normalized NOPAT Margin	-23.97%	-4.92%	-22.85%	-21.78%	-30.60%	-7.63%	-25.98%	-33.67%	-23.50%	-0.21%
Pre Tax Income Margin	-36.57%	-16.33%	-31.89%	-29.48%	-43.04%	-10.46%	-36.30%	-47.77%	-34.13%	-1.47%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-9.51	-0.34	-10.62	-10.18	-13.75	-5.20	-14.25	-16.24	-11.53	-0.45
NOPAT to Interest Expense	-6.66	-0.24	-7.50	-7.13	-9.62	-3.64	-10.08	-11.41	-8.07	-0.11
EBIT Less CapEx to Interest Expense	-14.43	-0.57	-11.77	-13.48	-16.45	-6.92	-17.23	-17.55	-13.71	-2.79
NOPAT Less CapEx to Interest Expense	-11.58	-0.47	-8.65	-10.43	-12.33	-5.36	-13.06	-12.73	-10.25	-2.45
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Below are key trends for Treace Medical Concepts (TMCI) drawn from the quarterly statements over the last four years. The focus is on top-line momentum, profitability, cash flows, and balance-sheet dynamics that may matter to retail investors.

Q4 2024 revenue jumped to $68.71M, up from $45.09M in Q3 2024, signaling stronger quarterly demand and a positive near-term trajectory.
Gross margin remained robust around 80% in 2024 quarters (Q4 2024 gross margin about $55.48M on $68.71M revenue; Q3 2024 about $36.13M on $45.09M), indicating efficient cost of goods sold relative to sales.
Q4 2024 net income narrowed to a small loss (-$0.50M) from larger quarterly losses in prior quarters, suggesting improving operating leverage.
Net cash from investing activities was positively recurring in 2024 quarters (Q4 +$3.42M, Q3 +$5.76M, Q2 +$2.24M, Q1 +$3.76M), reflecting cash inflows from asset sales or investments.

Financing cash flows remained modestly positive across 2024 quarters (Q4 +$0.026M, Q3 +$0.008M, Q2 +$0.311M, Q1 +$0.185M), indicating ongoing external funding support.
Net change in cash and equivalents in Q4 2024 narrowed to -$0.76M from -$6.07M in Q3 2024, suggesting a reduction in quarterly cash burn.
Operating cash flow remained negative in all 2024 quarters, illustrating continuing cash burn despite revenue growth and margin stability.

Nevertheless, net income remained negative across 2024 quarters (Q4 2024 consolidated net income around -$0.50M; prior quarters saw larger losses), indicating ongoing profitability challenges.
Net cash from continuing operating activities was negative across 2024 quarters (overall operating cash flow negative), underscoring persistent cash-flow tightness despite revenue gains.
Earnings per share were negative across the period (Q4 2024 basic EPS -$0.01, diluted -$0.01; similarly negative in earlier quarters), reflecting continued losses on a per-share basis.

05/06/26 03:46 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Treace Medical Concepts' Financials

When does Treace Medical Concepts' financial year end?

According to the most recent income statement we have on file, Treace Medical Concepts' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Treace Medical Concepts' net income changed over the last 2 years?

Treace Medical Concepts' net income appears to be on an upward trend, with a most recent value of -$55.74 million in 2024, rising from -$42.82 million in 2022. The previous period was -$49.53 million in 2023. Find out what analysts predict for Treace Medical Concepts in the coming months.

What is Treace Medical Concepts' operating income?

Treace Medical Concepts' total operating income in 2024 was -$55.69 million, based on the following breakdown:

Total Gross Profit: $168.26 million
Total Operating Expenses: $223.63 million

How has Treace Medical Concepts' revenue changed over the last 2 years?

Over the last 2 years, Treace Medical Concepts' total revenue changed from $141.84 million in 2022 to $209.36 million in 2024, a change of 47.6%.

How much debt does Treace Medical Concepts have?

Treace Medical Concepts' total liabilities were at $104.20 million at the end of 2024, a 8.6% decrease from 2023, and a 5.8% increase since 2022.

How much cash does Treace Medical Concepts have?

In the past 2 years, Treace Medical Concepts' cash and equivalents has ranged from $11.35 million in 2024 to $19.47 million in 2022, and is currently $11.35 million as of their latest financial filing in 2024.

How has Treace Medical Concepts' book value per share changed over the last 2 years?

Over the last 2 years, Treace Medical Concepts' book value per share changed from 1.09 in 2022 to 1.81 in 2024, a change of 66.2%.

Related Companies

Financial statements for NASDAQ:TMCI last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Treace Medical Concepts (TMCI) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Treace Medical Concepts' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Treace Medical Concepts (TMCI) Financials

Annual Income Statements for Treace Medical Concepts

Quarterly Income Statements for Treace Medical Concepts

Annual Cash Flow Statements for Treace Medical Concepts

Quarterly Cash Flow Statements for Treace Medical Concepts

Annual Balance Sheets for Treace Medical Concepts

Quarterly Balance Sheets for Treace Medical Concepts

Annual Metrics And Ratios for Treace Medical Concepts

Quarterly Metrics And Ratios for Treace Medical Concepts

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Treace Medical Concepts' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools